Synergistic FGF21-Inducing Systems for Personalized Nutrition and Health

Publication ID: 24-11857579_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic FGF21-Inducing Systems for Personalized Nutrition and Health,” Published Technical Disclosure No. 24-11857579_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857579_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,579.

Summary of the Inventive Concept

The present inventive concept integrates FGF21-inducing Bifidobacterium strains with cutting-edge technologies such as AI, IoT, blockchain, and new materials to create a more powerful system for personalized nutrition planning, FGF21 level monitoring, and data security.

Background and Problem Solved

The original patent disclosed a composition for promoting the secretion of FGF21, but it had limitations in terms of personalization, data tracking, and security. The new inventive concept addresses these limitations by incorporating synergistic combinations of technologies to provide a more comprehensive and effective solution.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for personalized nutrition planning, which includes a database of user profiles, a database of FGF21-inducing Bifidobacterium strains, and a machine learning module for recommending a personalized FGF21-inducing Bifidobacterium strain to a user based on their profile and health goals. Additionally, the system includes a method for monitoring FGF21 levels in a subject using a wearable IoT device and a cloud-based analytics platform. Furthermore, a blockchain-based system is used to secure and track FGF21-related data, ensuring data integrity and confidentiality. The composition for promoting FGF21 secretion is also enhanced with a graphene-based material for improving the bioavailability of the bacterium. Finally, an AI-powered genomics tool is used to predict FGF21 responsiveness in a subject by analyzing their genetic profile and identifying genetic markers associated with FGF21 responsiveness.

Novelty and Inventive Step

The new claims introduce novel synergistic combinations of FGF21-inducing Bifidobacterium strains with AI, IoT, blockchain, and new materials, which provide a more comprehensive and effective solution for personalized nutrition planning, FGF21 level monitoring, and data security. The inventive step lies in the integration of these distinct technologies to create a more powerful system that overcomes the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different AI algorithms for personalized nutrition planning, the integration of additional IoT devices for more comprehensive health tracking, or the development of new materials for enhancing the bioavailability of the bacterium. Variations of the blockchain-based system could include the use of different consensus algorithms or the integration of additional security protocols.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the personalized nutrition and health industries, with potential applications in areas such as precision medicine, health and wellness, and food technology. The target market includes companies and organizations involved in personalized nutrition, health monitoring, and data security, as well as individuals seeking personalized health solutions.

Field of Art

Biotechnology and personalized medicine, specifically focusing on microbiome-based interventions for metabolic health and FGF21 modulation. Requires expertise in microbiology, genomics, machine learning, and health informatics

Person of Ordinary Skill (PHOSITA) Profile

A researcher or engineer with advanced degrees in biotechnology or biomedical engineering, familiar with probiotic strain characterization, data analytics, and personalized health technologies. Possesses interdisciplinary knowledge spanning microbiology, computational methods, and health monitoring systems

Obviousness Rationale

A person having ordinary skill would recognize that the PTD represents predictable combinations of known technologies applied to the source patent's core innovation of Bifidobacterium strain-based FGF21 modulation. The disclosed technological integrations (AI, IoT, blockchain) represent standard approaches for enhancing and monetizing biomedical innovations. The variations demonstrate routine engineering adaptations that would be obvious to a skilled practitioner seeking to extend the original patent's commercial and scientific potential.

Obvious Combinations & Variations

Source Patent Element
Bifidobacterium breve M-16V strain for modulating physiological parameters
PTD Variation
Adding machine learning recommendation system for personalized strain selection
Obviousness Reasoning
Predictable application of AI/ML techniques to optimize probiotic interventions, representing a known method of personalizing medical treatments
Source Patent Element
Method of administering Bifidobacterium for metabolic modulation
PTD Variation
Incorporating IoT wearable devices for real-time FGF21 level tracking
Obviousness Reasoning
Routine integration of monitoring technologies with existing medical interventions, utilizing standard sensor and data collection techniques
Source Patent Element
Composition containing Bifidobacterium bacterium
PTD Variation
Enhancing bacterial composition with graphene-based materials for improved bioavailability
Obviousness Reasoning
Known approach in biotechnology for improving drug/bacterial delivery, representing a predictable materials science enhancement
Source Patent Element
Method of administering Bifidobacterium for physiological modulation
PTD Variation
Implementing blockchain-based data security and tracking system
Obviousness Reasoning
Standard technological approach for securing and managing sensitive medical data, representing an obvious administrative enhancement
Source Patent Element
Bifidobacterium strain associated with metabolic regulation
PTD Variation
Developing AI-powered genomic analysis for predicting individual FGF21 responsiveness
Obviousness Reasoning
Predictable application of computational genomics to personalize medical interventions, representing a known technique in precision medicine
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857579 and the present published technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious, as they represent routine combinations of known technologies applied to the foundational probiotic intervention method. The disclosed system integrations and technological enhancements constitute obvious extensions that would be readily conceived by a skilled practitioner seeking to optimize and expand the original patent's core innovation.

Original Patent Information

Patent NumberUS 11,857,579
TitleComposition for promoting the secretion of FGF21
Assignee(s)Morinaga Milk Industry Co., Ltd.